Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia caused by 2019-nCOV Infection ()
UC-MSCs cell number/50 mL/bag, on 1st, 3rd, 5th, and 7th days after enrolment
Treatment of COVID 19 Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogenic Adipose Derived Mesenchymal Stem Cells ()
A Phase 1/2a Study of the Safety and Efficacy of BX-U001 for the Treatment of Severe COVID-19 Pneumonia with Moderate to Severe ARDS ()
Single infusion of hUC-MCS product at dose of 0.5 million cells/kg
Biological: human umbilical cord mesenchymal stem cells+ supportive care
Incidence of infusion-related adverse events [time frame-day 3] and incidence of any treatment emergent adverse events and treatment emergent serious adverse events [time frame: day 28]
A Prospective Double-blind, Randomized, Parallel, Placebo controlled Pilot Clinical Trial for the Evaluation of the Efficacy and Safety of Two Doses of WJ-MSC in Patients with ARDS Secondary to Infection by COVID-19 ()
Experimental-Wharton-jelly MSCs on day 1 and day 3
A Pilot, Open-label, Randomised Controlled Clinical Trial to Investigate Early Efficacy of CYP-001 in Adults Admitted to Intensive Care with Respiratory Failure ()
Experimental: CYP-001 IV infusion of 2 million Cymerus MSCs/kg body weight
Biological- CYP-001
Trend in trajectory of PaO2/FiO2 ratio [time frame- 7 days]
A Multicentre, Randomised, Case controlled, Double-Blind, Ascending-dose study of Extracorporeal MSC in COVID-19 Subjects with Acute Kidney Injury Receiving Renal Replacement Therapy ()
Experimental: low dose and high dose SBI-101 device containing MSCs
Biological- SBI-101
Safety and tolerability as measured by incidence of IP-related serious adverse events [time frame- adverse events through day 180]
HBPCOV01: Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Patients with Post COVID-19 Syndrome.
Autologous adipose-derived MSCs with a treatment duration of 14 weeks
Intermediate size Expanded Access of Remesremcel-L, Human Mesenchymal Stromal Cells, for Multisystem Inflammatory Syndrome in Children Associated with Coronavirus Disease (COVID 19) ()
Remestecel-L – participants may receive upto 2 infusions of L within a 5-day period Drug: hydrocortisone receiving and diphenhydramine receiving participants 30 minutes prior to the infusion of remestemcel-L
Biological: remestemcel-L Drug: hydrocortisone and diphenhydramine